Anti-phospho-AKT (Ser473), DyLight(TM) 488 conjugated, clone 17B6.B11.A12.C3.G7.G12 / Rockland Product-Datasheet 200-341-268
Tel:+49-40 - 85 32 600
0800 - 24 66 651 free call
Fax: +49-40 - 85 32 60-22
0800 - 24 66 652 free call
Anti-phospho-AKT (Ser473), DyLight(TM) 488 conjugated, clone 17B6.B11.A12.C3.G7.G12
Size: 100 µg
Akt phospho S473 Dylight 488 Conjugated Antibody Properties
Anti-AKT pS473 (MOUSE) Monoclonal Antibody DyLight™ 488 Conjugated - 200-341-268
Known Cross Reactivity
human, mouse, rat, monkey
Monoclonal 17F6.B11 IgG1 kappa
ELISA : 1:4,000-1:20,000
IF Microscopy : >1:5,000
FlowCytometry : User Optimized
Western Blot : 1:10,000 - 1:25,000
Immunochemistry: 20 ug/ml
Other Dilution: User Optimized
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Restore with deionized water (or equivalent)
0.01% (w/v) Sodium Azide
10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Akt phospho S473 Dylight 488 Conjugated Antibody Description
AKT is a component of the PI-3 kinase pathway and is activated by phosphorylation at Ser 473 and Thr 308. AKT is a cytoplasmic protein also known as AKT1, Protein Kinase B (PKB) and rac (related to A and C kinases). AKT is a key regulator of many signal transduction pathways. AKT Exhibits tight control over cell proliferation and cell viability. Overexpression or inappropriate activation of AKT is noted in many types of cancer. AKT mediates many of the downstream events of PI 3-kinase (a lipid kinase activated by growth factors, cytokines and insulin). PI 3-kinase recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus. AKT has two main roles: (i) inhibition of apoptosis; (ii) promotion of proliferation.
This monoclonal antibody was produced by repeated immunizations with a synthetic peptide corresponding to residues surrounding S473 of human AKT1 protein.
Post Translational Modification
Store vial at 4 °C prior to restoration. For extended storage aliquot contents and freeze at -20 °C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.
This monoclonal antibody is suitable for immunofluorescence microscopy, FLISA and western blotting. Expect a band approximately 56 kDa in size corresponding to phosphorylated AKT protein by western blotting in the appropriate cell lysate or extract. This phospho-specific monoclonal antibody reacts with human and mouse AKT pS473 and shows minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide. Specific conditions for reactivity should be optimized by the end user.
This product was purified from concentrated tissue culture supernate by Protein A chromatography. This antibody is specific for human and mouse AKT protein phosphorylated at S473. A BLAST analysis was used to suggest cross-reactivity with AKT pS473 from human, mouse, rat and chimpanzee sources based on 100% homology with the immunizing sequence. Cross-reactivity with AKT from other sources has not been determined. Cross-reactivity with AKT2 and AKT3 has not been determined.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 326, Gilbertsville, Pennsylvania, USA.